Patents Assigned to GlaxoSmithKline Intellectual Property Development Limited
-
Publication number: 20230295313Abstract: The present invention relates generally to antibodies in the treatment of human disease and reduction of adverse events related thereto. More specifically, the present invention relates to the use of IL 1RAP (Interleukin-1 receptor accessory protein) binding proteins (including anti-IL 1RAP 0 antagonist antibodies) and their use as treatment and prevention of human disease.Type: ApplicationFiled: June 22, 2020Publication date: September 21, 2023Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: John G. Emery, Qi Fei, Shiyong Gong, Sanjay Kumar, Fang Ren, Teddy Yang, Hua Ying
-
Publication number: 20230279106Abstract: The present disclosure relates to compositions for treating CD96 mediated diseases, and related methods.Type: ApplicationFiled: September 2, 2022Publication date: September 7, 2023Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Yan Y. DEGENHARDT, Jun GUAN, Kenneth William HANCE, Peter Joseph MORLEY
-
Publication number: 20230192842Abstract: Chimeric antigen receptors (CARs) which include an antigen binding protein that binds to a discontinuous epitope on human claudin-3 comprising at least N38 and E153 of SEQ ID NO:13 are described. Also described herein includes polynucleotides encoding the antigen binding protein, the CARs, immune effector cells containing the CARs, pharmaceutical compositions containing the immune effector cells, and methods of treating cancer with the immune effector cells.Type: ApplicationFiled: September 22, 2022Publication date: June 22, 2023Applicant: GlaxoSmithKline Intellectual Property Development LimitedInventor: Thomas Southgate
-
Patent number: 11649238Abstract: The invention relates to compounds of formula (I) which are inhibitors of kinase activity, pharmaceutical formulations containing the compounds and their uses in treating and preventing viral infections and disorders caused or exacerbated by the viral infection wherein R1, R2, R3, R4a, R4b, R4c, R5, W, X, Y and Z are defined herein.Type: GrantFiled: January 15, 2019Date of Patent: May 16, 2023Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Nicholas Paul Barton, Sophie Marie Bertrand, Kenneth David Down, Matthew Gray
-
Patent number: 11649289Abstract: The present invention provides methods for increasing expression of ICOS on an effector T cell comprising contacting said effector T cell with an anti-PD-1 antibody. The present invention also provides methods for decreasing expression of ICOS on a regulatory T cell comprising contacting said regulatory T cell with an anti-PD-1 antibody. The present invention provides methods for increasing sensitivity to an agent directed to ICOS in a human comprising administering to the human an anti-PD1 antibody. The present invention also provides methods of treating cancer in a human in need thereof comprising administering an anti-PD-1 antibody and an anti-ICOS antibody to said human, wherein the anti-PD-1 antibody increases T cell sensitivity to the ICOS antibody.Type: GrantFiled: August 3, 2017Date of Patent: May 16, 2023Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Sabyasachi Bhattacharya, Paul M. Bojczuk, Heather L. Jackson, Mili Mandal, Hong Shi, Sapna Yadavilli, Niranjan Yanamandra
-
Patent number: 11643407Abstract: The present invention relates to indane compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators.Type: GrantFiled: May 16, 2019Date of Patent: May 9, 2023Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventor: Jeffrey K. Kerns
-
Publication number: 20230120185Abstract: Disclosed are compounds having the formula: wherein R1, R2, and R3 are as defined herein, and methods of making and using the same.Type: ApplicationFiled: September 27, 2022Publication date: April 20, 2023Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Niall Andrew Anderson, Deepak Bandyopadhyay, Alain Daugan, Frederic G. Donche, Patrick M. Eidam, Nicolas Eric Faucher, Nicolas S. George, Philip Anthony Harris, Jae U. Jeong, Bryan W. King, Clark A. Sehon, Gemma Victoria White, David Duff Wisnoski
-
Publication number: 20230101987Abstract: The invention relates to substituted pyridine derivatives that are inhibitors of the activity of DNA methyltransferase 1 (DNMT1). The invention also relates to pharmaceutical compositions comprising such compounds and methods of using such compounds in the treatment of cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases associated with inappropriate DNMT1 activity.Type: ApplicationFiled: October 14, 2022Publication date: March 30, 2023Applicant: GlaxoSmithKline Intellectual Property Development LimitedInventors: Andrew B. BENOWITZ, David T. Fosbenner, Bryan Wayne King, Stuart Paul Romeril
-
Patent number: 11613571Abstract: The present disclosure relates to compositions comprising antibody variants, for treating interleukin 5 (IL-5) mediated diseases, and related methods.Type: GrantFiled: May 21, 2019Date of Patent: March 28, 2023Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Chika Akinseye, Tejinder Bhinder, Li Cui, Steven Grant, Laura Hook, Alan Peter Lewis, Martin Anibal Orecchia
-
Publication number: 20230071675Abstract: Disclosed are compounds having the formula: wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.Type: ApplicationFiled: May 17, 2022Publication date: March 9, 2023Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Adam Kenneth CHARNLEY, Michael G DARCY, Jason W. DODSON, Xiaoyang DONG, Terry V. HUGHES, Jianxing KANG, Lara LEISTER, Yiqian LIAN, Yue LI, John F. MEHLMANN, Neysa NEVINS, Joshi M. RAMANJULU, Joseph J. ROMANO, Gren Z. WANG, Guosen YE, Daohua ZHANG
-
Publication number: 20230051209Abstract: The present invention relates to a composition comprising bacteria of the Delftia genus, specifically a composition comprising Delftia tsuruhatensis as well as the bacteria itself for use in the prevention of malaria transmission and methods of using the compositions for reducing malaria and/or malaria parasite transmission.Type: ApplicationFiled: July 10, 2020Publication date: February 16, 2023Applicant: GlaxoSmithKline Intellectual Property Development LimitedInventors: Alfonso MENDOZA LOSANA, Janneth RODRIGUES
-
Patent number: 11577082Abstract: Devices and methods for the stimulation of neural signaling of an apical splenic nerve, the device having a transducer for placement on or around the apical splenic nerve, and a signal generator to generate a signal that stimulates or inhibits the neural activity of the apical splenic nerve to produce a physiological response. The transducer has at least one electrode, and the signal generator is a voltage or current source. The stimulation electrical signal has a frequency of between 1 Hz and 50 Hz.Type: GrantFiled: November 8, 2017Date of Patent: February 14, 2023Assignees: Galvani Bioelectronics Limited, GlaxoSmithKline Intellectual Property Development Limited, Université de Nice Sophia-Antipolis, Centre Nationale de La Recherche ScientifiqueInventors: Philippe Blancou, Nicolas Glaichenhaus, Arun Sridhar
-
Patent number: 11566347Abstract: The present invention relates to methods of selecting, screening, engineering, making and modifying antibodies that have improved bioavailability upon subcutaneous administration to a human. Antibodies and variant antibodies with improved bioavailability upon subcutaneous administration to a human are also described.Type: GrantFiled: May 12, 2020Date of Patent: January 31, 2023Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Valeriu Damian, Austin Keith Doyle, Laura Maria Halo, Emma R. Harding, Xuan Hong, Alan Peter Lewis, Mark Uden
-
Patent number: 11555040Abstract: The invention is directed to compounds of formula (I), and salts thereof. The compounds are inhibitors of kinase activity, in particular PI3-kinase activity.Type: GrantFiled: April 16, 2018Date of Patent: January 17, 2023Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Andrew Baxter, Sophie Marie Bertrand, Matthew Campbell, Kenneth David Down, Curt Dale Haffner, Julie Nicole Hamblin, Zoe Alicia Henley, William Henry Miller, Eric Philippe Andre Talbot, Jonathan Andrew Taylor
-
Patent number: 11547704Abstract: The invention is directed to substituted piperidine derivatives. Specifically, the invention is directed to compounds according to Formula IIII: wherein A, B, X, Y, L1, L2, L3, R1, R2, R3, R4, R5, R6, R9, z2, z4, z5, and z6 are as defined herein, and salts thereof.Type: GrantFiled: June 11, 2020Date of Patent: January 10, 2023Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Jeffrey Michael Axten, Mui Cheung, Michael P. Demartino, Hilary Schenck Eidam, Raghava Reddy Kethiri, Biswajit Kalita
-
Publication number: 20220411425Abstract: The invention relates to a compound having the structure: or a pharmaceutically acceptable salt thereof, along with pharmaceutical compositions and therapeutic methods thereof.Type: ApplicationFiled: June 1, 2021Publication date: December 29, 2022Applicants: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, VIIV HEALTHCARE COMPANYInventors: Martha Alicia DE LA ROSA, John F. MILLER, B. Narasimhulu NAIDU, Vicente SAMANO, David TEMELKOFF, Emile Johann VELTHUISEN
-
Patent number: 11535833Abstract: The present disclosure provides engineered carboxyesterase enzymes that have the ability to catalyze amide bond formation. Also provided are polynucleotides encoding the carboxyesterase enzymes, host cells capable of expressing the engineered carboxyesterase enzymes, and methods of using the engineered carboxyesterase enzymes to make commercially valuable amides. Also provided are amides that are made using the engineered carboxyesterase enzymes.Type: GrantFiled: December 13, 2018Date of Patent: December 27, 2022Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Kristin K. Brown, Brent M. Dorr, Douglas E. Fuerst, Katherine Joyce Honicker, Lydia Sanchez Jordan, James Patrick Morrison, Nikolay V. Plotnikov, Markus Schober, Rama Voladri
-
Patent number: 11530238Abstract: The present invention relates to a method of purifying a recombinant polypeptide from Host Cell Proteins (HCP), the method comprising: (a) applying a solution comprising the recombinant polypeptide and HCP to a superantigen chromatography solid support, (b) washing the superantigen chromatography solid support with a wash buffer comprising caprylate and arginine; and (c) eluting the recombinant polypeptide from the superantigen chromatography solid support.Type: GrantFiled: September 6, 2017Date of Patent: December 20, 2022Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Andre C. Dumetz, Kent E. Goklen, Nicholas E. Levy, Jessica Rachel Molek, Andrew S. Thomson, Kenneth G. Yancey
-
Patent number: 11492361Abstract: The invention relates to compounds of Formula (I), salts thereof, combinations, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.Type: GrantFiled: October 5, 2020Date of Patent: November 8, 2022Assignees: GlaxoSmithKline Intellectual Property Development Limited, The University of North Carolina at Chapel Hill, ViiV Healthcare CompanyInventors: Richard M. Dunham, David Margolis, Vincent Wing-Fai Tai, Jun Tang
-
Patent number: 11485710Abstract: Disclosed are compounds having the formula: wherein R1, R2, and R3 are as defined herein, and methods of making and using the same.Type: GrantFiled: January 22, 2021Date of Patent: November 1, 2022Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Niall Andrew Anderson, Deepak Bandyopadhyay, Alain Claude-Marie Daugan, Frederic G. Donche, Patrick M. Eidam, Nicolas Eric Faucher, Nicolas S. George, Philip Anthony Harris, Jae U. Jeong, Bryan W. King, Clark A. Sehon, Gemma Victoria White, David Duff Wisnoski